Summary of Relay Therapeutics FY Conference Call Company Overview - **Company**: Relay Therapeutics (NasdaqGM: RLAY) - **Location**: Boston, Massachusetts - **Financial Position**: Well-capitalized with cash reserves projected to last until 2029 [2] Key Initiatives - **RLY-2608**: A first-in-class, PI3K mutant-selective inhibitor - **Phase 3 Trial**: Initiated for post-CDK4/6 treated metastatic breast cancer patients [2] - **Triplet Combinations**: Ongoing trials with RLY-2608, fulvestrant, ribociclib, and temaciclib for CDK4/6 naive metastatic breast cancer patients [2][3] - **Vascular Malformations**: Exploring RLY-2608 for conditions driven by PI3K alpha mutations, targeting a large unserved population [3] Competitive Landscape - **China's Biotech Innovation**: Acknowledged as a significant factor influencing Relay's R&D and business development strategy, focusing on first-in-class targets due to competitive pressures [4] AI Integration - **AI in Drug Discovery**: AI is viewed as a tool to enhance efficiency in drug discovery, but not as a complete solution. Human involvement remains crucial [5][6] Regulatory Environment - **Regulatory Interactions**: Limited impact from recent regulatory changes, with most interactions occurring in the previous year [7] RLY-2608 Mechanism and Efficacy - **Mechanism of Action**: RLY-2608 is designed to selectively inhibit mutant PI3K alpha, avoiding side effects associated with non-selective inhibitors [8][9] - **Clinical Data**: - **Efficacy**: 39% confirmed objective response rate and 10.3 months median progression-free survival (PFS) in a subset of 52 patients [12][14] - **Safety Profile**: Low rates of high-grade hyperglycemia and other adverse events compared to existing treatments [15][17] Market Opportunity - **Breast Cancer**: Approximately 13,000 PI3K alpha mutated patients in the U.S., with potential to double in the frontline setting, representing a multi-billion dollar total addressable market (TAM) [22][38] - **Vascular Malformations**: Estimated 170,000 patients with PI3KCA mutant-driven disease in the U.S., with significant potential for chronic therapy [45][46] Clinical Trials - **Rediscover 2 Phase 3 Trial**: Enrolling 540 patients, comparing RLY-2608 plus fulvestrant to fulvestrant plus Capivasertib, with primary endpoint of PFS [18][20] - **Vascular Malformations Trial**: Initiated in Q1 2025, focusing on three biologically active doses of RLY-2608 [44] Platform and Technology - **Dynamo® Platform**: Combines computational and experimental approaches to enhance drug discovery efficiency [49][50] - **Anton II Supercomputer**: Previously instrumental in early discoveries, now supplemented by cloud computing capabilities [54] Conclusion - **Future Outlook**: Relay Therapeutics is positioned to leverage its innovative drug development strategies and AI integration to address significant unmet medical needs in oncology and beyond, with RLY-2608 as a key asset in its portfolio [56]

Company Overview - Relay Therapeutics, Inc. is a clinical-stage precision medicine company focused on transforming the drug discovery process through advanced computational and experimental technologies [4] - The company aims to enhance small molecule therapeutic discovery in targeted oncology and genetic disease indications [4] Leadership Appointment - Claire Mazumdar, Ph.D., has been appointed to the Board of Directors of Relay Therapeutics, effective June 9, 2025 [1] - Dr. Mazumdar brings extensive strategic and operational experience in clinical-stage oncology, which will be valuable as the company prepares to initiate its Phase 3 ReDiscover-2 trial in breast cancer [2][3] Dr. Mazumdar's Background - Dr. Mazumdar is the founding CEO of Bicara Therapeutics and has held significant roles in business development and corporate strategy at Rheos Medicines and Third Rock Ventures [3] - She holds a B.S. in biological engineering from MIT, an MBA from Stanford, and a Ph.D. in cancer biology from Stanford [3] Clinical Development Focus - Relay Therapeutics is preparing to initiate the Phase 3 ReDiscover-2 trial, which focuses on breast cancer [2] - The company utilizes its Dynamo® platform to address previously intractable protein targets in drug discovery [4]

Core Insights - Relay Therapeutics is a clinical-stage precision medicine company focused on transforming the drug discovery process through advanced computational and experimental technologies [2] Group 1: Company Overview - Relay Therapeutics aims to bring life-changing therapies to patients by integrating cutting-edge computational and experimental approaches [2] - The company utilizes its Dynamo® platform to target previously intractable protein targets, enhancing small molecule therapeutic discovery in oncology and genetic diseases [2] Group 2: Upcoming Events - Management will participate in two fireside chats in June 2025, specifically at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Global Healthcare Conference on June 11 [3] - The fireside chats will be webcast live and available for replay for up to 30 days after the events [1]

Core Insights - Relay Therapeutics is a clinical-stage precision medicine company focused on transforming the drug discovery process through advanced computational and experimental technologies [2] Financial Results Announcement - Relay Therapeutics will report its first quarter 2025 financial results and corporate highlights on May 5, 2025, after U.S. financial markets close [1] Company Overview - The company utilizes its Dynamo® platform, which integrates various computational and experimental approaches to target previously challenging protein targets in drug discovery [2] - Relay Therapeutics aims to enhance small molecule therapeutic discovery specifically in targeted oncology and genetic disease indications [2]